DSIP

How a course is commonly described

1. 1
   Nights 1-2Community-reported

   Community pages describe starting at 100 mcg subcutaneously about an hour before bed and expecting little at this stage, since the peptide is framed as shifting sleep architecture rather than sedating. The same pages note that no human study has used this route or this dose.

2. 2
   Nights 3-7Community-reported

   This is where guides place the first reported change in sleep depth, and where they set their decision point: step from 100 mcg to 200 mcg if nothing has shifted after 3-4 nights, and treat night 5 as the earliest honest assessment. One physician page states that a non-responder will usually be clear by night 7 at 200 mcg.

3. 3
   Nights 8-14Community-reported

   The short-course protocols hold 200 mcg here, with 300 mcg listed for days 11-14 if nothing has changed, and describe the full reported effect as established by the end of a 14-night block. Reducing the dose is the advice given for next-morning drowsiness.

4. 4
   Weeks 2-8 (longer courses)Community-reported

   Not every guide stops at two weeks. One 2026 protocol holds 200 mcg once daily for an 8-week block, with 5 days on and 2 days off offered as a variation, which is several times longer than any course ever given to a person in a published study.

5. 5
   BreakCommunity-reported

   A 2-4 week off period before any repeat is the common convention, with 3-4 courses a year, and the stated reasons are that reported sleep changes carry over for a few weeks and that off periods may prevent adaptation. Neither reason has a published study behind it.

6. 6
   Clinical comparisonClinical

   The human record is a programme of five small double-blind studies using single and repeated slow intravenous injections, in which sleep induction took about an hour, the effect lasted up to 20 hours, and disturbed sleep was reported to normalize after four consecutive injections. Slow injection was described as essential, and no study tested the nightly subcutaneous course above.

• Every nightly subcutaneous figure in circulation, from 100 mcg to 300 mcg, comes from vendor and forum practice. The FDA's 2026 review states there is no effectiveness and no safety data for DSIP by the subcutaneous route, which is exactly the route and the 1 mg/mL product that was nominated for compounding.
• The published human studies infused the peptide slowly into a vein at 25-35 nmol/kg, roughly 1.5-2.5 mg for an adult, and ran for 3-7 nights at most. Animal pharmacokinetics put the plasma half-life under 10 minutes, which is why the early investigators framed the long-lasting effects as downstream rather than as sustained exposure.
• Results conflict rather than accumulate: two independent double-blind studies in chronic insomnia found no clinically meaningful change, the one study that tested the stress-hormone claim directly found none, and FDA concluded the evidence is insufficient for insomnia, narcolepsy and opioid withdrawal while flagging immunogenicity and poor characterization of the material being sold.